<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287689</url>
  </required_header>
  <id_info>
    <org_study_id>SIGNS</org_study_id>
    <nct_id>NCT01287689</nct_id>
  </id_info>
  <brief_title>Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study</brief_title>
  <acronym>SIGNS</acronym>
  <official_title>An Open, Uncontrolled, Non-interventional Observational Cohort Outcome Study of Immunoglobulins in 3 Indications: Primary and Secondary Immunodeficiencies and Neurological Auto-immune Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional, epidemiological study assesses long-term outcomes in subjects
      receiving immunoglobulins (IgG) for any treatment purpose, irrespective of the regimen
      prescribed by the treating physician, under routine clinical conditions in Germany.

      Long-term outcome data are collected on patient characteristics in the various indications,
      drug utilization of intravenous and subcutaneous IgG (e.g. treatment and dosing patterns),
      effectiveness (i.e. number of infections), tolerability, health related quality of life, and
      economic variables (number of hospitalizations, sick-leave days etc.) with the possibility to
      estimate direct costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In view of the broad range of indications in immunodeficiency and immunomodulation, it is of
      interest to document the use of IgG under the conditions of everyday practice and to analyze
      the endpoints (outcomes). A prospective cohort study such as this is an important evidence
      source for such rare diseases as those mentioned above. The aim of this outcome study is to
      fill the gap of the lack of long-term data in these rare diseases treated with IgG.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Immunoglobulin IgG dosage</measure>
    <time_frame>up to 54 months</time_frame>
    <description>Dosage of immunoglobulins (IgG); frequency of IgG administrations; days of treatment with IgG; duration of infusion of IgG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>up to 54 months</time_frame>
    <description>For immunodeficiencies (primary PID and secondary SID):
frequency of infections; degree of severity of infections (SBIs); duration of antibiotic treatment; necessity of antibiotic treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological and muscular function (for neurological auto-immune diseases only)</measure>
    <time_frame>up to 54 months</time_frame>
    <description>Grip strength (dynamometer) Electrophysiology (EMG, ENG); Inflammatory Neuropathy Cause and Treatment (INCAT) disability score; EDSS, annual relapse rate; Myasthenia Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of manifest auto-immune disease within the follow-up period(for neurological auto-immune diseases only).</measure>
    <time_frame>up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomic parameters</measure>
    <time_frame>up to 54 months</time_frame>
    <description>Number of sick-leave days Number of medical visits Days of hospitalisation due to infections or due to disability or loss of function Degree of disability</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">685</enrollment>
  <condition>Primary Immunodeficiency (PID)</condition>
  <condition>Secondary Immunodeficiency (SID)</condition>
  <condition>Neurological Autoimmune Disease</condition>
  <arm_group>
    <arm_group_label>Patient treated with any IgG</arm_group_label>
    <description>Any marketed SC or IV IgG can be documented</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunoglobulin G (IgG)</intervention_name>
    <description>Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.</description>
    <arm_group_label>Patient treated with any IgG</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory or hospital-based patients (no age restriction)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either gender with primary, severe secondary immunodeficiency and
             recurrent infections or neurological autoimmune diseases

          -  Naïve to IgG, or pre-treated with IgG

          -  Subject or parent/legally authorized representative has provided written informed
             consent.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm Kirch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Pittrow, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Borte, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Fachbereich Pädiatrische Rheumatologie, Immunologie und Infektiologie am Klinikum St. Georg gGmbH Leipzig, Akademisches Lehrkrankenhaus der Universität Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Baumann, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie, Medizinische Hochschule Hannover (MHH), Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manfred Hensel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mannheimer Onkologie Praxis, Mannheim, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dörte Huscher</last_name>
    <role>Study Director</role>
    <affiliation>Epidemiologie, Rheumaforschungszentrum Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcel Reiser, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>PIOH - Praxis Internistische Onkologie, Hämatologie, Köln, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Stangel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Klinik für Neurologie, Medizinische Hochschule Hannover (MHH), Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralph Gold, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Klinik für Neurologie, St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudia Sommer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Neurologische Klinik und Poliklinik, Universitätsklinik Würzburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Neurologie, St. Josefs-Hospital der Ruhr-Univ.</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical Pharmacology</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie, Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie, Medizinische Hochschule (MHH).</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachbereich Pädiatrische Rheumatologie, Immunologie und Infektiologie am Klinikum St. Georg gGmbH Leipzig, Akademisches Lehrkrankenhaus der Universität</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mannheimer Onkologie-Praxis</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kirch W, Gold R, Hensel M, Fasshauer M, Pittrow D, Huscher D, Reiser M, Stangel M, Baumann U, Borte M. [Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]. Med Klin (Munich). 2010 Sep;105(9):647-51. doi: 10.1007/s00063-010-1105-8. Epub 2010 Sep 28. German.</citation>
    <PMID>20878302</PMID>
  </reference>
  <results_reference>
    <citation>Borte M, Baumann U, Pittrow D, Hensel M, Fasshauer M, Huscher D, Reiser M, Stangel M, Gold R, Kirch W; Liste der aktuell beitragenden Zentren, sortiert nach Postleitzahlen (mindestens ein Patient zum 1.3.2012). [Immunoglobulins in PID, SID and neurological autoimmune disease]. Dtsch Med Wochenschr. 2012 Mar;137(13):675-80. doi: 10.1055/s-0032-1304844. Epub 2012 Mar 20. Review. German.</citation>
    <PMID>22434180</PMID>
  </results_reference>
  <results_reference>
    <citation>Stangel M, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Kirch W, Pittrow D, Reiser M, Gold R. Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry. J Clin Immunol. 2013 Jan;33 Suppl 1:S67-71. doi: 10.1007/s10875-012-9789-6. Epub 2012 Sep 14.</citation>
    <PMID>22976553</PMID>
  </results_reference>
  <results_reference>
    <citation>Stangel M, Gold R, Pittrow D, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Reiser M, Sommer C. Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. Ther Adv Neurol Disord. 2016 May;9(3):165-79. doi: 10.1177/1756285616629869. Epub 2016 Feb 16.</citation>
    <PMID>27134672</PMID>
  </results_reference>
  <results_reference>
    <citation>Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, Stangel M, Fasshauer M, Gold R, Hensel M. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. Eur J Haematol. 2017 Aug;99(2):169-177. doi: 10.1111/ejh.12900. Epub 2017 Jun 21.</citation>
    <PMID>28467615</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-interventional trial</keyword>
  <keyword>immunodeficiency</keyword>
  <keyword>outcome study, registry</keyword>
  <keyword>long-term outcomes, drug utilization</keyword>
  <keyword>effectiveness, treatment patterns</keyword>
  <keyword>patient characteristics under real life conditions</keyword>
  <keyword>factors for treatment success</keyword>
  <keyword>long-term tolerability</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

